Navigation Links
Using cell phones to detect harmful airborne substances
Date:4/4/2012

RIVERSIDE, Calif. (www.ucr.edu) The lab of a University of California, Riverside Bourns College of Engineering professor was named on Tuesday, April 3 after Innovation Economy Corporation, a Riverside company that plans to commercialize his research focused on using mobile devices, such as cell phones, to detect harmful airborne substances in real-time.

The technology being developed by Nosang Myung, professor and chair of the Department of Chemical and Environmental Engineering, and Innovation Economy Corporation has the potential to be adapted in many industries. These include agriculture (detecting concentrations of pesticides), industry (monitoring evaporation and leaks when using or storing combustible gases), homeland security (warning systems for bio-terrorism) and the military (detecting chemical warfare agents).

"This collaborative relationship is key to ensuring research conducted in our laboratories can be commercialized." Myung said.

Reza Abbaschian, dean of the Bourns College of Engineering, said he is appreciative of Innovation Economy Corporation's support of the research.

"We are equally appreciative of the support they offer through their mission of connecting our faculty with government and industry and identifying ways to commercialize their discoveries for the benefit of society," Abbaschian said.

Myung's research is licensed by start-up company Nano Engineering Applications, Inc., which was created and funded by Innovation Economy Corporation.

Nano Engineering Applications focuses on commercializing patent pending, air-borne chemical detection technology. The company's cost-effective and scalable fabrication techniques allow research to be transformed into portable devices that detect minute quantities of harmful air-borne substances.

"This is a truly a unique opportunity to collaborate with a world class research university to transform untapp
'/>"/>

Contact: Sean Nealon
sean.nealon@ucr.edu
951-827-1287
University of California - Riverside
Source:Eurekalert

Page: 1 2

Related biology news :

1. NJIT professor finds engineering technique to identify disease-causing genes
2. Research shows that the pill does not deserve its reputation for causing weight gain
3. Planetary "first family" discovered by astronomers using Gemini and Keck Observatories
4. Planetary first family discovered by astronomers using Gemini and Keck Observatories
5. Using water to understand human society, from the industrial revolution to global trade
6. ESA satellites focusing on the Arctic
7. Using the other guys toolkit: Similarities of pumping blood, oil examined
8. Bangladesh Voter Registration Project Now Using MegaMatcher Biometric Technology to Detect and Prevent Duplicate Registrations
9. City of Newark first in nation using cars to power grid
10. Warmer climate causing huge increase in tree mortality across the West
11. Cancer-causing gene discovery suggests new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/2/2015)... June 25, 2015 ... addition of the "Natural Language Processing Market ... IVR, OCR, Pattern & Image Recognition) - Worldwide ... The key vendors occupying the market ... Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute Inc., ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... enzyme viewed as an executioner, because it can push cells ... of cell death, researchers at Emory University School of Medicine ... by leading scientists to rethink how proposed anti-cancer and anti-inflammatory ... to work. The results are described in this week,s ...
... may be behind a progressively earlier bloom of a crucial ... the entire food chain and carbon cycling in the region. ... Diego, along with colleagues in Portugal and Mexico, plotted the ... the ocean food chainin the Arctic Ocean and found the ...
... WEST LAFAYETTE, Ind. - A Purdue University scientist ... of improved plant growth regulators that are expected to ... professor of horticulture, said the growth inhibitors block the ... throughout the plant, controls growth processes. Current growth regulators ...
Cached Biology News:Jekyll and Hyde: Cells' executioner can also stave off death 2Scripps oceanography researchers discover arctic blooms occurring earlier 2New growth inhibitors more effective in plants, less toxic to people 2
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... 2015  With over 60,000 customers across the globe, ISN improves the efficiency and ... with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers ... Headquartered in Dallas, TX , ISN has ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Premier Research Group plc, the,international pharmaceutical services ... buyout. As a result, the company is no,longer ... Stock Exchange. The UK-based,private equity firm ECI Partners ... Simon Yaxley, Chief Executive Officer of Premier Research,Group, ...
... Inc. (OTC,Bulletin Board: AGGX.OB) a New York-based biotechnology ... targeted anti-angiogenic drugs, announced the,appointment of William Garland ... Hoffmann La Roche, Inc., has directed research and,development ... companies such as,Centaur Pharmaceuticals, Atairgin Technologies, Lpath Therapeutics, ...
... 10 Spine surgeons at Pine Creek Medical,Center ... of a,cutting-edge surgical procedure that utilizes a patient,s ... Douglas Won, Michael Rimlawi, and Francisco J. Battle, ... stem cells,during routine spinal procedures and delivering those ...
Cached Biology Technology:Premier Research Announces Completion of Management Buyout 2AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs 2AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs 3Spine Surgeons at Pine Creek Medical Center Take the Lead in Utilizing Stem Cell Technologies in Surgical Procedures 2
... Features, Special optically clear polystyrene formulation ... performance in immunoassay applications , Plates ... lower coefficients of variation , Eight-well ... elimi-nating strip loss while in use even ...
...
... Easy-Titer Human IgM Assay Kit to address ... easy-to-perform assay for Human IgM that eliminates ... incorporates a simple mix-and-read assay that allows ... 15-500 ng/ml in approximately 30 minutes. The ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
Biology Products: